ARESTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Arestin, and what generic alternatives are available?
Arestin is a drug marketed by Orapharma and is included in one NDA.
The generic ingredient in ARESTIN is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Arestin
A generic version of ARESTIN was approved as minocycline hydrochloride by WATSON LABS on December 30th, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARESTIN?
- What are the global sales for ARESTIN?
- What is Average Wholesale Price for ARESTIN?
Summary for ARESTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 95 |
| Clinical Trials: | 7 |
| Patent Applications: | 2,826 |
| Drug Prices: | Drug price information for ARESTIN |
| What excipients (inactive ingredients) are in ARESTIN? | ARESTIN excipients list |
| DailyMed Link: | ARESTIN at DailyMed |
Recent Clinical Trials for ARESTIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bausch Health Companies, INC. | Phase 4 |
| University of Minnesota - Clinical and Translational Science Institute | Phase 4 |
| University of Minnesota | Phase 4 |
Pharmacology for ARESTIN
| Drug Class | Tetracycline-class Drug |
| Physiological Effect | Decreased Prothrombin Activity |
US Patents and Regulatory Information for ARESTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orapharma | ARESTIN | minocycline hydrochloride | POWDER, EXTENDED RELEASE;DENTAL | 050781-001 | Feb 16, 2001 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ARESTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Orapharma | ARESTIN | minocycline hydrochloride | POWDER, EXTENDED RELEASE;DENTAL | 050781-001 | Feb 16, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Orapharma | ARESTIN | minocycline hydrochloride | POWDER, EXTENDED RELEASE;DENTAL | 050781-001 | Feb 16, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ARESTIN
See the table below for patents covering ARESTIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 2263596 | ⤷ Sign Up | |
| Japan | 4749672 | ⤷ Sign Up | |
| Australia | 2003223384 | DISPENSING APPARATUS AND CARTRIDGE | ⤷ Sign Up |
| Canada | 2479995 | DISTRIBUTEUR ET CARTOUCHE (DISPENSING APPARATUS AND CARTRIDGE) | ⤷ Sign Up |
| Colombia | 5611079 | APARATO DISPENSADOR Y CAPSULA | ⤷ Sign Up |
| Denmark | 2263596 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
